Leadership change puts IDEAYA Biosciences in focus
IDEAYA Biosciences (IDYA) has moved long time Chief Scientific Officer Dr. Michael White into the role of President, Research and Development, effective 28 September 2026, drawing fresh attention to the stock.
IDEAYA Biosciences has seen short term momentum cool, with the share price down 5.62% over the past week and 9.03% over the past month, even though the year to date share price return is 7.12% and the 1 year total shareholder return sits at 35.10%. This suggests that investors may be reassessing near term execution risk after a strong run while still recognizing the longer term story.
Scan beyond IDEAYA Biosciences and see how other oncology and biotech players are positioned by running through our curated 20 high quality undiscovered gems.
IDEAYA Biosciences now pairs a fresh R&D leadership structure with a cooled share price after a strong year. Do those conditions still skew the risk reward toward new buyers or toward patience?
Most Popular Narrative: 31% Undervalued
Analysts following IDEAYA Biosciences see a fair value of $52.75 per share against the last close at $36.26. This frames the leadership shift as part of a story where valuation hinges on pipeline execution and eventual commercial follow through.
Progress on the RTOR NDA submission for darovasertib in metastatic uveal melanoma, combined with Fast Track designation and management commentary around an HLA agnostic label, points to a potential first commercial product for IDEAYA Biosciences that could open a new revenue stream.
See why 1 investors see IDEAYA Biosciences as 31% undervalued.
According to the most widely followed narrative, that fair value of $52.75 is based on a 7.54% discount rate and hinges on revenue eventually reaching $435.3 million with earnings of $75.0 million and a P/E of 103.3x by about 2029. Those figures sit above current levels, with the business currently reporting a loss of $175.0 million on $234.1 million of revenue and analysts not expecting profitability in the next three years.
The same storyline assumes IDEAYA Biosciences can convert its broad precision oncology pipeline into multiple registrational programs, from darovasertib in uveal melanoma through to IDE849 in small cell lung cancer and the MTAP focused franchise. Any change in trial design, competitive positioning in DLL3 therapies, or regulatory timing for darovasertib could therefore have a direct effect on whether that $52.75 narrative fair value appears conservative or optimistic relative to the current $36.26 share price.
Result: Fair Value of $52.75 (UNDERVALUED)
Still, the narrative around IDEAYA Biosciences can change quickly if regulators slow the darovasertib review or DLL3 competitors blunt IDE849's commercial potential.
Find out about the key risks to this IDEAYA Biosciences narrative.
Another View on IDEAYA Biosciences' Valuation
IDEAYA Biosciences looks very different once the focus shifts from analyst targets to the current P/S ratio. The stock trades on a P/S of 14.9x compared with 12.1x for the wider US Biotechs group and a fair ratio of 3.1x. That gap signals a lot of expectation packed into the price, so the key question is how comfortable you are with paying that much upfront for a business that is still loss making.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals around IDEAYA Biosciences can feel urgent when headlines move faster than filings. Take a moment to pressure test the upside and the weak spots for yourself using the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond IDEAYA Biosciences?
If the IDEAYA Biosciences story has sharpened your focus, do not stop here. The right watchlist today can shape the opportunities you notice tomorrow.
- Spot potential mispricings early and review 29 high quality undervalued stocks that pair stronger fundamentals with pricing that has not fully caught up yet.
- Prioritise resilience first and sift through the 31 resilient stocks with low risk scores that score well on balance sheet strength and business stability.
- Hunt for financially healthy outliers and scan the list of solid balance sheet and fundamentals (25 results) to see which companies combine cleaner finances with room for a stronger story.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com